A new report estimates that a majority of needed manufacturing jobs could go unfilled over the next decade if changes aren't made.
Taiho Oncology Inc.'s combination tablet, recently approved by the FDA, will be dispensed by...
According to Hemp, Inc., the Hemp Industry continues to garner media attention.
Adaptimmune Therapeutics plc. announced plans to locate its U.S. headquarters and clinical...
Glancy Prongay & Murray LLP announces that it is investigating potential claims on behalf of investors of Amicus Therapeutics, Inc.
Teva Pharmaceutical Industries Ltd. announced the exclusive launch of generic capsules in the United States.
Sunshine Biopharma Inc. announces that it has acquired a U.S. patent.
Medline Industries, Inc. announced that it will initiate a voluntary nationwide recall of lot of tablets.
Ohio sent a forceful letter to Washington on Friday asserting that the state believes it can obtain a lethal-injection drug from overseas without violating any laws.
Bristol-Myers Squibb Company announced that the FDA has approved their drug, for intravenous use, for the treatment of patients with metastatic NSCLC with progression on or after platinum-based chemotherapy.
On the second and final day of Systech’s 2015 Uniquity Global Conference, speakers delved into topics such as global counterfeiting, company safety, and consumer safety.
The first day of the 2015 Uniquity conference concludes, but not without giving attendees much to ponder on regarding serialization.
Vertex Pharmaceuticals Incorporated announced that the FDA has accepted for review a sNDA for a drug that treats CF in people ages 2 and older who have one of 23 residual function mutations.
Nektar Therapeutics announced that it has submitted an IND application to the FDA for its lead immuno-oncology candidate.
Marathon Pharmaceuticals announced that the FDA has granted rare pediatric disease designation for a potential treatment for patients with DMD.
Amicus Therapeutics, Inc. Sued for Securities Fraud After Revealing Its NDA Will Not Be Filed This YearOctober 7, 2015 5:08 pm | by PR Newswire | News | Comments
Amicus Therapeutics, Inc. and its Chief Executive Officer, John F. Crowley, were named as defendants in a lawsuit.
Illinois Claimants Opt-In to Takeda Pharmaceutical’s $2.4 Billion Product Liability Resolution ProgramOctober 7, 2015 4:51 pm | by Business Wire | News | Comments
Meyers & Flowers Law Firm announces Illinois claimants opt-in to Takeda Pharmaceutical’s $2.4 billion liability resolution program.
In advance of the 2015-2016 flu season, Focus Diagnostics announced that its SimplexaT Flu A/B & RSV Direct Kit has received clearance from the FDA for additional strains.
Express Scripts has decided to cover two new drugs that lower cholesterol.